nVerses Capital’s Insmed INSM Stock Holding History

nVerses Capital’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,200	Closed	-$348K	–	1191
2024 Q2	$348K	Buy	+5,200	New	+$202K	0.21%	159

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

nVerses Capital's INSM Position: Q3 2024 in Review

nVerses Capital sold out of Insmed (INSM) in Q3 2024, closing a stake of 5,200 shares — an estimated $348K sold.

nVerses Capital first reported a position in INSM in Q2 2024 and held it in 1 quarter. The position peaked at $348K in Q2 2024. 413 funds tracked by Wall St. Rank hold INSM as of Q3 2024.

nVerses Capital reported no remaining Insmed position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 5,200 Insmed shares in Q3 2024, an estimated $348K.
nVerses Capital first reported a position in Insmed in Q2 2024 and held it in 1 quarter.
nVerses Capital's Insmed position peaked at $348K in Q2 2024.
413 funds tracked by Wall St. Rank held Insmed as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.